プロの翻訳者、企業、ウェブページから自由に利用できる翻訳レポジトリまで。
6.1. opretholde betingelserne for anvendelse af zinkbacitracin som anført under pkt. 1 for
6.1 conditions of use of zinc bacitracin indicated under item 1 for - poultry, excluding ducks and geese, - swine, - calves, lambs and kids, - animals bred for fur be maintained ?
fællesskabsinstitutionernes argumentation, som er udtrykt i den anfægtede forordning med hensyn til zinkbacitracin, er følgelig klar og utvetydig.
last, it should be borne in mind that at that time scientists were contemplating the possibility that bacitracin zinc would be used to treat vre, a particularly significant clinical problem in human medicine.
alt efter omstændighederne i de enkelte tilfælde er godkendelserne af zinkbacitracin blevet givet uden tidsmæssig begrænsning eller for en bestemt periode.
the fact that it might be necessary to adopt such further measures does not establish that the contested regulation was inappropriate.
alpharma har nedlagt påstand om annuuation af forordning nr. 2821/98 i sin helhed eller for så vidt angår zinkbacitracin.
orders pfizer to bear its own costs and to pay those incurred by the council, including those relating to the proceedings for interim relief;
for at beskytte menneskers sundhed bør godkendelsen af følgende antibiotika inddrages: zinkbacitracin, spiramycin, virginiamycin og tylosinphosphat;
whereas, for the sake of protecting human health, the authorisations for the antibiotics bacitracin zinc, spiramycin, virginiamycin and tylosin phosphate should be withdrawn;
en medlemsstat anmodede for nylig kommissionen om at ændre de i bilag ii, del a, fastsatte betingelser for anvendelsen af zinkbacitracin således:
besides, the commission was asked by a member state to amend as follows the conditions of use of zinc bacitracin stated in annex ii, section a :
alpharma kritiserer i det væsentlige fællesskabsinstitutionerne for ikke at have baseret deres videnskabelige evaluering af de risici, der er særligt forbundet med zinkbacitracin, på passende videnskabelige oplysninger.
on 5 november 1998, alpharma was informed by the fédération européenne des fabricants d'adjuvants pour la nutrition animale ('fefana') that the commission had drawn up a draft proposal for a regulation including bacitracin zinc on the list of antibiotics banned as additives in feedingstuffs.
den videnskabelige komité for foder blev anmodet om at undersøge betingelserne for anvendelsen af zinkbacitracin og flavophospholipol, som er godkendt ved fællesskabets direktiver, samt udtale sig om følgende spørgsmål:
the scientific committee for animal nutrition was requested to examine the conditions of use of zinc bacitracin and flavophospholipol, authorized by community directives, and to give an opinion on the following questions.
forekomsten af sådanne gavnlige virkninger kan nemlig ikke i sig selv bevise, at forbuddet mod zinkbacitracin som vækstfremmemiddel er en åbenbart uegnet foranstaltning, når det gør det muligt at mindske resistensen hos dyr og risikoen for overførsel til mennesker.
however, it remains to examine whether the community institutions made a manifest error of assessment in concluding, on the basis of the other factual evidence, that the use of bacitracin zinc as a growth promoter constituted a risk to human health.
det skal endelig bemærkes, at det også i denne periode blev overvejet af en række videnskabelige eksperter, hvorvidt det var muligt at anvende zinkbacitracin i behandlingen af vre, som er et særligt stort klinisk problem inden for humanmedicin.
it is reckoned that the consequences of any ban in those countries on antibiotics in feedingstuffs will be more negative than those observed in sweden, both in terms of animal health (and thus in terms of antibiotic use for therapeutic or preventive purposes) and in economic terms (greater loss of profits).
alpharma bemærker endvidere, at forbuddet mod zinkbacitracin indebærer en større risiko for inficering af kød med fækale bakterier som følge af brud på fjerkræets tarmvæg under forarbejdningen, for det er bevist, at behandling af fjerkræ med dette produkt styrker deres tarme.
it is clear, on the contrary, that they could reasonably take the view that there were serious reasons concerning human health, within the meaning of article 3a(e) of directive 70/524, why bacitracin zinc, as an antibiotic with a dual use as an additive in feedingstuffs and at the same time as a medicinal product for human use, should be confined to medical use.
alpharma har subsidiært anført, at fællesskabsinstitutionerne med henblik på vedtagelsen af den anfægtede forordning burde have anvendt to forskellige procedurer. dels skulle man, for så vidt angår andre tilsætningsstoffer end zinkbacitracin, have fulgt den procedure, der foreskrives i artikel 24 i
on 2 february 1998 the kingdom of sweden, with a view to a decision being taken by 31 december 1998 and in accordance with annex xv to the act of accession (see paragraph 2 above), submitted a request for the adaptation of directive 70/524, together with a detailed scientific statement of reasons, seeking
(29) forbuddet mod antibiotikaene zinkbacitracin, spiramycin, virginiamycin og tylosinphosphat bør opfattes som en forebyggende sikkerhedsforanstaltning, der vil kunne revideres i lyset af de undersøgelser, som er blevet udført, og af det etablerede overvågningsprogram;
(29) whereas the prohibition on the use of the antibiotics bacitracin zinc, spiramycin, virginiamycin and tylosin phosphate ought to be perceived as an interim protective measure taken as a precaution, which could be reconsidered in the light of the investigations which will have been carried out and of the established surveillance programme;